NCT06865339 2026-04-13
TRIPL
Montefiore Medical Center
Phase 2 Recruiting
Clinical Trials
15 trialsNCT06738160 2026-03-20
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Fudan University
Phase 2 Recruiting
NCT05798845 2026-03-11
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Recruiting
NCT07082179 2026-02-11
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
NCT07330037 2026-01-09
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07169552 2025-12-17
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
HC Biopharma Inc.
Phase 2 Recruiting
NCT07181499 2025-09-30
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Betta Pharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT07198217 2025-09-30
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
Zibo Municipal Hospital
Phase 2 Recruiting
NCT06864624 2025-07-25
WU-KONG20
Tang-Du Hospital
Phase 2 Recruiting
NCT07085182 2025-07-25
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
Zibo Municipal Hospital
Phase 2 Recruiting
NCT06714708 2025-02-10
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT06532591 2024-12-20
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 2 Recruiting
NCT06479759 2024-06-28
ACCLAIM
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT06424821 2024-05-22
LungCadX
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT05286957 2023-03-17
Seagull
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting